---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-040238"
form_type: "8-K"
ticker: "MGX"
cik: "0001785279"
company_name: "Metagenomi Therapeutics, Inc."
filed_at: "2025-03-17T23:59:59+00:00"
generated_at: "2026-05-24T16:01:53.843829+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Metagenomi reports $248.3M cash; hemophilia A program on track for IND in 2026

## Summary
- Cash, cash equivalents, and marketable securities $248.3M as of Dec 31, 2024; runway into 2027.
- FY2024 R&D expense $109.2M (up from $94.4M); G&A expense $32.0M (up from $28.8M).
- Hemophilia A program MGX-001: sustained FVIII activity in NHP >16 months; IND submission expected 2026.
- Ionis collaboration: four Wave 1 targets in lead optimization; plans to nominate 1-2 DCs in 2025.
- Board addition: Eric Bjerkholt (CFO of Mirum Pharmaceuticals) joins audit and compensation committees.

## SEC filing metadata
- accession: 0000950170-25-040238
- form_type: 8-K
- ticker: MGX
- cik: 0001785279
- company_name: Metagenomi Therapeutics, Inc.
- filed_at: 2025-03-17T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1785279/000095017025040238/0000950170-25-040238-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1785279/000095017025040238/mgx-20250317.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-040238
- JSON: https://secwatch.observer/filing/0000950170-25-040238.json
- Plain text: https://secwatch.observer/filing/0000950170-25-040238.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.